Dual l-carnosine/aloe vera nanophytosomes with synergistically enhanced protective effects against methylglyoxal-induced angiogenesis impairment

• Main Authors: Darvishi, Behrad, Dinarvand, Rassoul, Mohammadpour, Hadiseh, Kamarul, Tunku, Sharifi, Ali Mohammad
• Format: Article
• Published: American Chemical Society 2021
• Subjects: R Medicine; RS Pharmacy and materia medica
• Online Access: http://eprints.um.edu.my/27879/
• Institution: Universiti Malaya

Microvascular complications are among the major outcomes of patients with type II diabetes mellitus, which are the consequences of impaired physiological functioning of small blood vessels and angiogenic responses in these patients. Overproduction and accumulation of methylglyoxal (MGO), a highly reactive dicarbonyl byproduct of glycolysis pathway, has been acclaimed as the main inducer of impaired angiogenic responses and microvascular dysfunction in diabetic patients with uncontrolled hyperglycemia. Hence, an effective approach to overcome diabetes-associated microvascular complications is to neutralize the deleterious activity of enhanced the concentration of MGO in the body. Owing to the glycation inhibitory activity of Aloe vera whole extract, and capability of L-carnosine, an endogenous dipeptide, in attenuating MGO's destructive activity, we examined whether application of a combination of L-carnosine and A. vera could be an effective way of synergistically weakening this reactive dicarbonyl's impaired angiogenic effects. Additionally, overcoming the poor cellular uptake and internalization of L-carnosine and A. vera, a nanophytosomal formulation of the physical mixture of two compounds was also established. Although L-carnosine and A. vera at whole studied combination ratios could synergistically enhance viability of human umbilical vein endothelial cells (HUVECs) treated with MGO, the 25:1 w/w ratio was the most effective one among the others (27 +/- 0.5% compared to 12 +/- 0.3 to 18 +/- 0.4%; F (4, 15) = 183.9, P < 0.0001). Developing dual nanophytosomes of L-carnosine/A. vera (25:1) combination ratio, we demonstrated superiority of the nanophytosomal formulation in protecting HUVECs against MGO-induced toxicity following a 24-72 h incubation period (17.3, 15.8, and 12.4% respectively). Moreover, 500 mu g/mL concentration of dual L-carnosine/A. vera nanophytosomes exhibited a superior free radical scavenging potency (63 +/- 4 RFU vs 83 +/- 5 RFU; F (5, 12) = 54.81, P < 0.0001) and nitric oxide synthesizing capacity (26.11 +/- 0.19 vs 5.1 +/- 0.33; F (5, 12) = 2537, P < 0.0001) compared to their physical combination counterpart. Similarly, 500 mu g/mL dual L-carnosine/A. vera nanophytosome-treated HUVECs demonstrated a superior tube formation capacity (15 +/- 3 vs 2 +/- 0.3; F (5, 12) = 30.87, P < 0.001), wound scratch healing capability (4.92 +/- 0.3 vs 3.07 +/- 0.3 mm/h; F (5, 12) = 39.21, P < 0.0001), and transwell migration (586 +/- 32 vs 394 +/- 18; F (5, 12) = 231.8, P < 0.001) and invasion (172 +/- 9 vs 115 +/- 5; F (5, 12) = 581.1, P < 0.0001) activities compared to the physical combination treated ones. Further confirming the proangiogenic activity of the dual L-carnosine/A. vera nanophytosomes, a significant shift toward expression of proangiogenic genes including HIF-1 alpha, VEGFA, bFGF, KDR, and Ang II was reported in treated HUVECs. Overall, dual L-carnosine/A. vera nanophytosomes could be a potential candidate for attenuating type II DM-associated microvascular complications with an impaired angiogenesis background.